Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine's Antidepressant Response and the Development of Ketamine Addiction.

Bonnet U.

J Psychoactive Drugs. 2015 Sep-Oct;47(4):276-85. doi: 10.1080/02791072.2015.1072653. Epub 2015 Aug 28.

PMID:
26317449
2.

Update to the study protocol for a randomized controlled trial comparing mindfulness-based cognitive therapy with maintenance anti-depressant treatment depressive relapse/recurrence: the PREVENT trial.

Kuyken W, Byford S, Byng R, Dalgleish T, Lewis G, Taylor R, Watkins ER, Hayes R, Lanham P, Kessler D, Morant N, Evans A.

Trials. 2014 Jun 10;15:217. doi: 10.1186/1745-6215-15-217.

3.

A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients.

Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, Lord S, Bisaga A, Aharonovich E, Levin F, McDowell D, Nunes EV.

Am J Addict. 2014 Jan-Feb;23(1):68-75. doi: 10.1111/j.1521-0391.2013.12065.x. Epub 2013 Jun 26.

4.

Treatment of comorbid alcohol use disorders and depression with cognitive-behavioural therapy and motivational interviewing: a meta-analysis.

Riper H, Andersson G, Hunter SB, de Wit J, Berking M, Cuijpers P.

Addiction. 2014 Mar;109(3):394-406. doi: 10.1111/add.12441. Epub 2014 Jan 16. Review.

5.

Integrated care for comorbid alcohol dependence and anxiety and/or depressive disorder: study protocol for an assessor-blind, randomized controlled trial.

Morley KC, Baillie A, Sannibale C, Teesson M, Haber PS.

Addict Sci Clin Pract. 2013 Nov 19;8:19. doi: 10.1186/1940-0640-8-19.

6.

12-step affiliation and attendance following treatment for comorbid substance dependence and depression: a latent growth curve mediation model.

Worley MJ, Tate SR, McQuaid JR, Granholm EL, Brown SA.

Subst Abus. 2013;34(1):43-50. doi: 10.1080/08897077.2012.691451.

7.

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.

Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. Epub 2013 Mar 21.

8.

Current status of co-occurring mood and substance use disorders: a new therapeutic target.

Pettinati HM, O'Brien CP, Dundon WD.

Am J Psychiatry. 2013 Jan;170(1):23-30. doi: 10.1176/appi.ajp.2012.12010112. Review.

9.

Treatment of the depressed alcoholic patient.

DeVido JJ, Weiss RD.

Curr Psychiatry Rep. 2012 Dec;14(6):610-8. doi: 10.1007/s11920-012-0314-7. Review.

10.

Group cognitive-behavioral therapy for clients with major depression in residential substance abuse treatment.

Watkins KE, Hunter S, Hepner K, Paddock S, Zhou A, de la Cruz E.

Psychiatr Serv. 2012 Jun;63(6):608-11. doi: 10.1176/appi.ps.201100201.

11.

Mediational relations between 12-Step attendance, depression and substance use in patients with comorbid substance dependence and major depression.

Worley MJ, Tate SR, Brown SA.

Addiction. 2012 Nov;107(11):1974-83. doi: 10.1111/j.1360-0443.2012.03943.x. Epub 2012 Aug 10.

12.

Comorbid depression and substance use disorder: longitudinal associations between symptoms in a controlled trial.

Worley MJ, Trim RS, Roesch SC, Mrnak-Meyer J, Tate SR, Brown SA.

J Subst Abuse Treat. 2012 Oct;43(3):291-302. doi: 10.1016/j.jsat.2011.12.010. Epub 2012 Mar 8.

13.

The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.

Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V; European Psychiatric Association.

Eur Psychiatry. 2012 Feb;27(2):129-41. doi: 10.1016/j.eurpsy.2011.06.003. Epub 2011 Dec 1.

PMID:
22137775
14.

Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR.

Addiction. 2012 Jan;107(1):131-41. doi: 10.1111/j.1360-0443.2011.03552.x. Epub 2011 Oct 10.

15.

Pregnenolone for cognition and mood in dual diagnosis patients.

Osuji IJ, Vera-Bolaños E, Carmody TJ, Brown ES.

Psychiatry Res. 2010 Jul 30;178(2):309-12. doi: 10.1016/j.psychres.2009.09.006. Epub 2010 May 21.

PMID:
20493557
16.

A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.

Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, Dackis CA, O'Brien CP.

Am J Psychiatry. 2010 Jun;167(6):668-75. doi: 10.1176/appi.ajp.2009.08060852. Epub 2010 Mar 15.

17.

The relationship between depression and smoking cessation outcomes in treatment-seeking substance abusers.

Sonne SC, Nunes EV, Jiang H, Tyson C, Rotrosen J, Reid MS.

Am J Addict. 2010 Mar-Apr;19(2):111-8. doi: 10.1111/j.1521-0391.2009.00015.x.

18.

Developing an integrated treatment for substance use and depression using cognitive-behavioral therapy.

Osilla KC, Hepner KA, Muñoz RF, Woo S, Watkins K.

J Subst Abuse Treat. 2009 Dec;37(4):412-20. doi: 10.1016/j.jsat.2009.04.006. Epub 2009 Jun 21.

19.

Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence.

Horsfall J, Cleary M, Hunt GE, Walter G.

Harv Rev Psychiatry. 2009;17(1):24-34. doi: 10.1080/10673220902724599. Review.

PMID:
19205964
20.

Effectiveness of topiramate for tobacco dependence in patients with depression; a randomised, controlled trial.

García Campayo J, Sobradiel N, Alda M, Mas A, Andrés E, Magallón R, Crucelaegui A, Sanz B.

BMC Fam Pract. 2008 May 7;9:28. doi: 10.1186/1471-2296-9-28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk